Radiopharm Theranostics

Contributing Author

Recent Articles by Radiopharm Theranostics

Dec-15	Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases RADX GlobeNewswire
Nov-18	Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer RADX GlobeNewswire
Nov-17	Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases RADX GlobeNewswire
Nov-12	Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204 RADX GlobeNewswire
Oct-20	Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs RADX GlobeNewswire
Oct-20	Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan RADX GlobeNewswire
Oct-01	Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 'HEAT' Dose Escalation Clinical Trial RADX GlobeNewswire
Jul-29	Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update RADX GlobeNewswire
Jul-28	Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01) RADX GlobeNewswire
Jul-22	Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board RADX GlobeNewswire
Jun-24	Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia RADX GlobeNewswire
Jun-11	Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases RADX GlobeNewswire
Jun-04	Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors RADX GlobeNewswire
Jun-02	Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake RADX GlobeNewswire
May-19	ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177 RADX GlobeNewswire
May-12	Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC) RADX GlobeNewswire
May-07	Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference RADX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.